Deal reached over FDA review of follow-on biotech drugs

A bipartisan group of senators plans to introduce a measure to give the FDA authority to approve follow-on versions of biotech drugs. The legislation from Democratic Sens. Edward Kennedy and Hillary Clinton and Republican Sens. Michael Enzi and Orrin Hatch allows for interchangeability of the follow-on biologic drugs but also gives biotechs four years of exclusivity before a generic maker can sell a biosimiliar and 12 years before a copycat version can go to market.

View Full Article in:

Bloomberg · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL